Skip to content

XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

Tag: immuno-oncology

October 22, 2026

A New Frontier in Cancer Therapy: GeorgiaMune and Menarini Join Forces

A Strategic Partnership in Immuno-Oncology The landscape of cancer treatment is evolving rapidly, and a recent announcement highlights a significant step forward. GeorgiaMune, a biotechnology company focused on innovative medical solutions, has entered into an exclusive global licensing and collaboration agreement with the Menarini Group. This partnership centers on the development of GIM-621, a promising…

Announcements

cancer-treatment, GeorgiaMune, GIM-621, immuno-oncology, Menarini Group, pr-newswire
November 30, 2023

Jaguar Health | Presents December 5 at the MedInvest Oncology Investor Conference

Jaguar Health, a leading pharmaceutical company specializing in innovative treatments for various diseases, is set to present at the prestigious MedInvest Oncology Investor Conference on December 5. This highly anticipated event brings together top experts, investors, and industry leaders in the field of oncology. Jaguar Health’s participation at this conference is a testament to their…

Conferences

clinical trials, immuno-oncology, national-department-of-health, oncology, pcsa, the-north-west-department-of-health

© XBioReport.com

Disclaimer: This site is for information only. Not investment advice.

Buy A Premium Report To Maximize Your Returns

The FREE bio tech stock catalyst report ONLY includes companies with catalysts within the current week. Often, this may not be enough time to capture the pre-catalyst stock price movements. For MAX RETURNS, buy a premium report below with longer outlooks, allowing you to discover earlier trade entries. Get positioned BEFORE a price move happens. Don’t miss out, maximize your return potential!

Choose your outlook window (each priced accordingly)

Get FREE Biotech Stock Catalyst Reports

Email